Natera, Inc.: insider trades · United States · SEC (Form 4)

About Natera, Inc.

Natera, Inc. is a U.S.-based molecular diagnostics company listed on the NASDAQ under the ticker NTRA, in the United States. For international investors, the company is best understood as a precision-medicine leader built around cell-free DNA (cfDNA) testing, with a founding story that dates back to 2004 and a long-term mission to change standards of care in genetic disease. Its operational center is in Austin, Texas, while it also runs laboratories in San Carlos, California. Natera combines molecular biology, bioinformatics, and increasingly AI-enabled analytics to detect and interpret genetic signals from a blood sample. The business is organized around three major areas. In women’s health, Panorama is the company’s flagship non-invasive prenatal test, used to screen for common chromosomal conditions in pregnancy. In oncology, Signatera is the core growth and strategic platform: a tumor-informed minimal residual disease (MRD) assay used for cancer recurrence monitoring, treatment response assessment, and longitudinal disease management. In organ health, Prospera supports transplant rejection surveillance, while Renasight addresses genetic causes of chronic kidney disease. This portfolio gives Natera exposure to multiple high-value clinical workflows rather than a single diagnostic niche. From a competitive standpoint, Natera positions itself as one of the leading cfDNA diagnostics companies, with differentiation based on assay design, clinical evidence, and an extensive publication record. The company highlights the strength of its validation studies, broad clinical utility, and the depth of its data assets. That said, the commercial footprint is still overwhelmingly U.S.-centric: international revenue remains relatively small, so reimbursement trends, physician adoption, and payer coverage in the United States are especially important to the investment case. Recent developments underscore the company’s momentum. On May 7, 2026, Natera reported first-quarter 2026 revenue of $696.6 million, up 38.8% year over year, supported by continued test volume growth, including strong oncology growth. During 2025 and early 2026, the company acquired Foresight Diagnostics, launched proprietary AI foundation models to speed diagnostic and therapeutic innovation, and secured an FDA approval for Signatera CDx in muscle-invasive bladder cancer. Natera therefore offers investors a growth-oriented healthcare diagnostics story with meaningful clinical optionality, but also with execution risk, heavy R&D intensity, and continued dependence on U.S. market adoption.